Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3294MR)

This product GTTS-WQ3294MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3294MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4847MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ5261MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ9467MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ3142MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ15819MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ9875MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ7935MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ14153MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW